Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Bayer hat ein Gesamteigenkapital von €30.7B und eine Gesamtverschuldung von €41.2B, wodurch sich der Verschuldungsgrad auf 134.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €106.9B bzw. €76.3B. Bayer Das EBIT des Unternehmens beträgt €9.2B, so dass der Zinsdeckungsgrad 11.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €6.3B.

Wichtige Informationen

134.1%

Verhältnis von Schulden zu Eigenkapital

€41.16b

Verschuldung

Zinsdeckungsgrad	11.3x
Bargeld	€6.34b
Eigenkapital	€30.69b
Gesamtverbindlichkeiten	€76.25b
Gesamtvermögen	€106.95b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BAYNDie kurzfristigen Aktiva des Unternehmens (€33.1B) übersteigen seine kurzfristigen Passiva (€25.0B).

Langfristige Verbindlichkeiten: BAYNDie kurzfristigen Vermögenswerte des Unternehmens (€33.1B) decken seine langfristigen Verbindlichkeiten (€51.2B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BAYNDie Nettoverschuldung im Verhältnis zum Eigenkapital (113.5%) wird als hoch angesehen.

Schulden abbauen: BAYNDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 92.1% auf 134.1% gestiegen.

Schuldendeckung: BAYNDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (19.4%) gedeckt.

Zinsdeckung: BAYNDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (11.3x Coverage) gut gedeckt.

Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

New major risk - Share price stability

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Now 54% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Now 38% undervalued after recent price drop

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 44% undervalued after recent price drop

Now 45% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Now 64% undervalued after recent price drop

Bayer Announces Pharmacodynamic Data on Kerendia

Investor sentiment deteriorates as stock falls 66%

Investor sentiment deteriorates as stock falls 66%

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 66%

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Investor sentiment deteriorates as stock falls 66%

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Investor sentiment deteriorates as stock falls 66%

Now 55% undervalued after recent price drop

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 66%

Now 44% undervalued after recent price drop

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen